Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Spruce Biosciences Inc
(NQ:
SPRB
)
0.8384
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Spruce Biosciences Inc
< Previous
1
2
Next >
Spruce Biosciences to Participate in May Investor Conferences
May 01, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
April 30, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
April 22, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Inc. (NASDAQ: SPRB) Making Surprising Moves in Tuesday Session
September 12, 2023
Via
Investor Brand Network
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 13, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
March 13, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 30, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
January 22, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
January 05, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
January 04, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
November 02, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
October 18, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Spruce Biosciences
Via
Business Wire
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 14, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
June 12, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
May 25, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
May 24, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala
May 22, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 15, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
May 04, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in May Investor Conferences
May 02, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
March 16, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
February 28, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces $53.6 Million Private Placement Financing
February 09, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
February 01, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
January 09, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan
January 06, 2023
Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and
Via
Spotlight Growth
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.